Moderna (MRNA) has experienced wide-sweeping developments recently. Despite an initial dip in stock, the company received a substantial $590M grant to develop mRNA pandemic influenza vaccines, particularly against avian flu, drawing significant attention. Moderna's RSV vaccine trials encountered a 'safety signal', which paused further vaccines for this potentially deadly childhood disease. Business magnate Larry Ellison was lauded as a potential savior for Moderna, especially as the stock surged following the news of a bird flu-related death in the US. However, a downgrade from Goldman Sachs led to another slump in Moderna's share price. Meantime, the firm's involvement in creating a norovirus vaccine as cases rise across the U.S and potential AI involvement in cancer vaccines have piqued investor interest. Yet, with lowered price targets from Evercore and Goldman Sachs and concerns regarding profitability, some remain skeptical about Moderna's future. Further, Moderna faces legal troubles as GSK accuses them of patent infringement regarding COVID and RSV vaccines. Despite a challenging landscape, Moderna reports encouraging data on a combo COVID-19/Influenza mRNA vaccine and secures a significant European supply deal. Nonetheless, the company's outlook remains unpredictable.
Moderna MRNA News Analytics from Tue, 14 Jul 2020 07:00:00 GMT to Fri, 31 Jan 2025 15:56:21 GMT -
Rating 0
- Innovation 8
- Information 6
- Rumor -6
